Cost‐effectiveness of universal esophageal cancer screening for newly diagnosed oral cancer patients
Journal of Gastroenterology and Hepatology · 2024
DOI: 10.1111/jgh.16771 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2024. Verfasst von Hui-Min Hsieh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, Kaohsiung Medical University, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Esophageal Neoplasms, Early Detection of Cancer, Mouth Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Kaohsiung Medical University Research Foundation, Ministry of Science and Technology, Ministry of Health and Welfare.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background and Aim Oral and esophageal cancers are globally prevalent, especially in East Asia. Over half of head and neck cancer patients developing second primary esophageal cancer (SPEC) were initially diagnosed with oral cavity cancer (OCC). This study assessed the cost‐effectiveness of universal endoscopic screening for early SPEC prevention in newly diagnosed OCC patients at different stages.
Methods
This study employed Markov cohort models to evaluate the cost‐effectiveness of endoscopic SPEC screening post‐OCC diagnosis (stages 0 to IV) between screened and non‐screened groups. Four surveillance frequencies were assessed: (i) one time, (ii) annual for 3 years, (iii) annual for 10 years, and (iv) annual for life. A hypothetical cohort of 100 000 cases across stages was compared for costs and quality‐adjusted life‐years (QALYs), discounted annually at 3%.
Results
All four screening strategies were beneficial for all OCC stages, especially for early‐stage patients, resulting in higher QALYs. Lifetime/annual screening from the payer's perspective proved most favorable, with incremental QALYs of 1.23 at stage 0 and 0.06 at stage IV. Incremental costs for this strategy ranged from NTD 121 331 (USD 4044) at stage 0 to NTD 13 032 (USD 434) at stage IV. Both incremental costs and incremental cost‐effectiveness ratio (ICER) values indicated cost savings from a societal perspective. The ICER values ranged from NTD −626 440 (USD −20 881) at stage 0 and NTD −475 021 (USD −15 834) at stage IV.
Conclusions
Overall, our study provided cost‐effectiveness evidences to understanding the cost‐effectiveness of endoscopic screening in OCC patients, particularly emphasizing the benefits of early and consistent screening.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Public Health, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
- Department of Community Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
- Center for Big Data Research, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Research Center for Environmental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
ORCID-Profile: Hui-Min Hsieh, Yi-Hsun Chen, Wen-Hung Hsu, Yao-Kuang Wang, Yen-Yun Wang, Shyng-Shiou F Yuan, I-Chen Wu
Förderung
- Kaohsiung Medical University Research Foundation
- Ministry of Science and Technology
- Ministry of Health and Welfare
- Kaohsiung Medical University Hospital
- Kaohsiung Medical University Research Center
- Ministry of Education
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Zitieren
APA
Hsieh, H. M., Ho, C. M., Chen, Y. H., Hsu, W. H., Wang, Y. K., Wang, Y. Y., Yuan, S. F., & Wu, I. C. (2024). Cost‐effectiveness of universal esophageal cancer screening for newly diagnosed oral cancer patients. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16771
Vancouver
Hsieh HM, Ho CM, Chen YH, Hsu WH, Wang YK, Wang YY, et al. Cost‐effectiveness of universal esophageal cancer screening for newly diagnosed oral cancer patients. Journal of Gastroenterology and Hepatology. 2024. doi:10.1111/jgh.16771
BibTeX
@article{Hsieh2024,
author = {Hsieh, Hui-Min and Ho, Chi-Mei and Chen, Yi-Hsun and Hsu, Wen-Hung and Wang, Yao-Kuang and Wang, Yen-Yun and Yuan, Shyng-Shiou F and Wu, I-Chen},
title = {Cost‐effectiveness of universal esophageal cancer screening for newly diagnosed oral cancer patients},
journal = {Journal of Gastroenterology and Hepatology},
year = {2024},
doi = {10.1111/jgh.16771}
}
EUVIMED